Aldeyra Therapeutics, Inc. (ALDX) Raised Price Target to $9, Analyst Says.

Aldeyra Therapeutics, Inc. (ALDX) has had its price target raised to $9 by JonesTrading, a potential upside of 66.98% from the current price. The FDA has accepted the company's NDA resubmission for its lead product, Reproxalap, aimed at dry eye disease. AbbVie is expected to pay $100 million upfront and share US profits if approved. The company's platform includes follow-on assets like ADX-629 and ADX-2191.